About Aldeyra Therapeutics Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://www.aldeyra.com/
Frequently Asked Questions
What is the 52-week range for ALDX?
The 52-week high is $5.93 and the 52-week low is $1.07.
What is the P/E ratio for ALDX?
The P/E ratio data is currently unavailable.
What is the dividend yield for ALDX?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -53.14%.
What is the Net Profit Margin?
Net Margin data is currently unavailable.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 7.04.
Analyst Recommendation Trends
Wall Street analyst consensus for ALDX over the last few months:
Latest ALDX News
Novo's Wegovy Pill Shows Weight Loss After Switching From Injections
NVO's Wegovy pill delivers an average weight loss of 4.1% after three months for adults switching from injectable GLP-1 therapies.
HC Wainwright & Co. Reiterates Neutral on Aldeyra Therapeutics, Maintains $2 Price Target
HC Wainwright & Co. analyst Matthew Caufield reiterates Aldeyra Therapeutics (NASDAQ:ALDX) with a Neutral and maintains $2 price target.
What's going on in today's after hours session
After the closing bell on Tuesday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session.
Aldeyra to Appeal FDA Rejection of Reproxalap for Dry Eye Disease
Aldeyra Therapeutics (NASDAQ:ALDX) said it plans to submit a formal dispute resolution request, or FDRR, to the FDA’s Office of New Drugs seeking review of the agency’s latest complete response letter for reproxalap, its investigational treatment for the signs and symptoms of dry eye disease. The c
Aldeyra Therapeutics Plans Formal FDA Dispute Resolution Request for Reproxalap After Third Complete Response Letter
Aldeyra Therapeutics intends to formally challenge the FDA’s March 2026 rejection of reproxalap for dry eye disease, with a Formal Dispute Resolution Request and meeting with the agency’s Office of New Drugs expected in the fourth quarter of 2026. Key Investor TakeawaysAldeyra Therapeutics (NASDAQ:ALDX) plans to submit a Formal Dispute Resolution Request seeking to appeal the FDA’s March 16, 2026 Complete Response Letter for reproxalap.
Aldeyra Fights Back Against FDA Rejection, Dispute Plan Triggers Rally
Aldeyra Therapeutics stock surges as the company files an FDA dispute resolution for its dry eye drug reproxalap following a rejection.
Merck Inks $2.1B Deal With Chinese Biotech to Expand Oncology Pipeline
MRK's $2.13 billion deal for SPR2015 adds a preclinical KRAS G12D inhibitor to its precision oncology pipeline, targeting a common cancer mutation.
Acadia's Daybue Patent Allowance Extends U.S. Protection to March 2041
ACAD gains a potential patent extension for Daybue to 2041, while strong sales growth and EU approval expand trofinetide's reach.
Aldeyra Therapeutics, Inc. (ALDX) Discusses FDRR and FDA Review Process for Reproxalap in Dry Eye Disease Transcript
Aldeyra Therapeutics, Inc. (ALDX) Discusses FDRR and FDA Review Process for Reproxalap in Dry Eye Disease September 29, 2026 8:00 AM EDTCompany...
BTIG Reiterates Buy on Aldeyra Therapeutics, Maintains $9 Price Target
BTIG analyst Thomas Shrader reiterates Aldeyra Therapeutics (NASDAQ:ALDX) with a Buy and maintains $9 price target.
Aldeyra Therapeutics Announces Intent to Submit Formal Dispute Resolution Request for Reproxalap to Treat Dry Eye Disease
CONCORD, Mass., September 29, 2026--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced intent to submit to the U.S. Food and Drug Administration (FDA) a Formal Dispute Resolution Request (FDRR) for reproxalap, an investigational drug candidate, for the treatment of dry eye disease. The FDRR, which is expected to be reviewed by the FDA’s Office of New Dr
Aldeyra Therapeutics to Host Regulatory Update Webcast
CONCORD, Mass., September 28, 2026--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced that the company will host a regulatory update webcast on Tuesday, September 29, 2026, at 8:00 a.m. ET. The update will focus on reproxalap, an investigational drug for the treatment of dry eye disease.
ACAD Stock Down 13% as Phase II Alzheimer's Study Misses Primary Goal
Acadia stock falls 13% after its Alzheimer's psychosis study narrowly misses its primary goal, though 60 mg results support continued phase III development.
IMVT Ends Cutaneous Lupus Erythematosus Program, Stock Down
Immunovant's IMVT-1402 misses its primary CLE goal, prompting the company to halt the program despite positive trends and a favorable safety profile.
ORKA Stock Down 5% Despite Positive Week 28 Psoriasis Efficacy Data
Oruka's ORKA-001 delivers deeper psoriasis clearance at week 28, but safety disclosures may have weighed on shares despite positive efficacy data.
Vertex Posts Positive Phase II Data on Kidney Disease Drug
VRTX announces positive AMPLIFIED data for inaxaplin, while completing AMPLITUDE enrollment and targeting interim results in early 2027.
AstraZeneca's Trixeo Secures Approval for Asthma in the EU
AZN's Trixeo wins EU approval for asthma, adding an indication backed by phase III data showing improved lung function.
AbbVie's Rinvoq Wins EU Approval in Juvenile Idiopathic Arthritis
ABBV's Rinvoq secures EU approval for pJIA in children, expanding ABBV's reach as clinical data show sustained improvements in disease activity.
Novo's CagriSema Outshines Zepbound in Key Phase III Weight-Loss Study
NVO's CagriSema delivers greater weight loss than Eli Lilly's tirzepatide in T2D and 21% weight loss in obesity, strengthening its late-stage pipeline.
AZN's Klygefa Gets CHMP Nod for Generalised Myasthenia Gravis in EU
AstraZeneca's Klygefa wins a positive EU recommendation for AChR-positive gMG, backed by phase III data and a convenient once-weekly treatment option.
Novo's Sogroya Gains CHMP Nod for Idiopathic Short Stature in the EU
NVO's Sogroya wins a positive CHMP opinion for idiopathic short stature in the EU, potentially broadening its pediatric growth disorder reach.
Novo's Denecimig Gets CHMP Nod for Hemophilia A in the European Union
NVO's denecimig wins a positive European opinion for hemophilia A, with flexible dosing and a potential 2026 launch.
XENE Files NDA for Epilepsy Drug, Falls on Depression Studies' Setback
Xenon files an FDA application for azetukalner in epilepsy as its depression studies face a temporary enrollment pause.
RARE Stock Up 13% on FDA Approval of Sanfilippo Syndrome Gene Therapy
Ultragenyx jumps 13% after FDA approval of Fayuvi, the first approved treatment for Sanfilippo syndrome Type A, backed by durable clinical data.
Kiniksa Pharmaceuticals Stock Rallies 41% in Three Months: Here's Why
KNSA is gaining momentum as Arcalyst sales surge and pipeline advances strengthen prospects for continued growth.
Novo Expands AI Push With Anthropic Deal to Accelerate Drug Discovery
NVO is expanding its AI strategy with Anthropic to tackle drug discovery challenges, boost R&D productivity and develop new medicines faster.
Gilead Expands Lenacapavir Access With New PAHO Deal in Latin America
GILD's PAHO deal expands twice-yearly lenacapavir access across Latin America and the Caribbean, adding 14 countries to its global access strategy.
GSK Inks $750M Deal to Add Experimental Blood Cancer Therapy
GSK's $750M Chimagen deal adds a trispecific TCE to its multiple myeloma portfolio, targeting two tumor antigens simultaneously.
Definium Reports Second Phase III Success in Anxiety Disorder Program
DFTX scores a second phase III GAD win as DT120 ODT delivers significant anxiety improvements, paving the way for FDA talks and a planned 2027 regulatory filing.
GSK Presents Jideytro Data for Potential Use in First-Line NSCLC
GSK's Jideytro delivers strong first-line NSCLC results, with high response rates and durable disease control supporting a planned FDA filing.
AbbVie's Atogepant Meets Goal in Late-Stage Menstrual Migraine Study
ABBV's atogepant delivers positive LUNA data in menstrual migraine, potentially expanding its migraine franchise and addressing an unmet need.
Bayer Secures FDA Nod for Sevabertinib's First-Line Use in NSCLC
BAYRY's sevabertinib wins first-line NSCLC approval. The company advances BAY 3670549 into a phase II AFib study.
Spyre's Anti-IL-23 Antibody Meets Goal in Ulcerative Colitis Study
SYRE's SPY003 posts positive phase II UC data, strengthening Spyre's multi-mechanism IBD strategy.
Verastem Stock Skyrockets 121% in 3 Months: Here Is Why
VSTM shares surge 121% as Avmapki Fakzynja Co-Pack gains commercial traction and VS-7375 advances across key cancer studies.
CAPR Stock Skyrockets 144% in a Month: What Is Driving the Rally?
Capricor shares jump in a month as positive phase III data and renewed FDA engagement revive hopes for deramiocel approval in DMD.
SMMT Stock Soars on NSCLC Drug Survival Data Beating Keytruda in China
Summit Therapeutics stock jumps 17% after ivonescimab showed a significant overall survival benefit over Keytruda in a China phase III lung cancer study.
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-06-09 | Miller-Rich Nancy | +3,318 | - | - |
| 2026-06-09 | Miller-Rich Nancy | +70,000 | - | - |
| 2026-06-09 | Clark William D | +2,323 | - | - |
| 2026-06-09 | Clark William D | +70,000 | - | - |
| 2026-06-09 | Walker Neal | +3,318 | - | - |
| 2026-06-09 | Walker Neal | +70,000 | - | - |
| 2026-06-09 | Bronstein Ben | +4,977 | - | - |
| 2026-06-09 | Bronstein Ben | +5,309 | - | - |
| 2026-06-09 | Bronstein Ben | +70,000 | - | - |
| 2026-06-09 | Phillips Gary M. | +4,977 | - | - |
| 2026-06-09 | Phillips Gary M. | +6,636 | - | - |
| 2026-06-09 | Phillips Gary M. | +70,000 | - | - |
| 2026-06-09 | DEPTULA-HICKS DARLENE M | +9,756 | - | - |
| 2026-06-09 | DEPTULA-HICKS DARLENE M | +84,557 | - | - |
| 2026-06-09 | DOUGLAS RICHARD | +2,323 | - | - |
| 2026-06-09 | DOUGLAS RICHARD | +19,909 | - | - |
| 2026-06-09 | DOUGLAS RICHARD | +70,000 | - | - |
| 2026-06-03 | Brady Todd C | +250,000 | $1.6738 | $418,450 |
| 2026-03-27 | Brady Todd C | +632,318 | - | - |
| 2026-03-27 | Brady Todd C | +1,880,510 | - | - |
| 2026-03-19 | DOUGLAS RICHARD | +70,000 | $1.4 | $98,000 |
| 2026-03-18 | Alfieri Michael | +5,000 | $1.42 | $7,100 |